FDA: Certain COVID-19 tests must evaluate how variants affect performance
The Food and Drug Administration today required certain COVID-19 test developers to evaluate how SARS-CoV-2 mutations impact their test’s performance and update the labeling for the product accordingly. The new conditions for emergency use authorization pertain to certain authorized molecular, antigen and serological tests.
Related News Articles
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
A JAMA article co-authored by AHA Chief Physician Executive Chris DeRienzo, M.D., and leaders from Vizient highlights that hospitals and health systems have…
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
Kelley Sava, associate vice president of simulation at Advocate Health, and Brian Bjoern, M.D., patient safety manager at Laerdal Medical, share how simulation…